Completed PHASE4 INTERVENTIONAL 2-arm NCT00044655

Switching Medication to Treat Schizophrenia

Effectiveness of Switching Antipsychotic Medications

Sponsor: Icahn School of Medicine at Mount Sinai

Interventions Aripiprazole Olanzapine Quetiapine Risperidone Ziprasidone

Updated 8 times since 2017 Last updated: Mar 28, 2016 Started: Jul 31, 2001 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Schizophrenia and is currently completed. Icahn School of Medicine at Mount Sinai leads this study, which shows 8 recorded versions since 2001 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jul 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH)

Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.